Gilead: epatite cronica delta, novità al Congresso AISF su terapie e impatti dei trattamenti
(Adnkronos) - L'epatite cronica delta è la forma più aggressiva di tutte le forme di epatite cronica virale. Si ritiene che in Italia ci siano circa tra 6 e 10 mila i soggetti anti delta positivi. Alla luce di questo, il Congresso Aisf, presso l’Auditorium della Tecnica a Roma è stato un momento cruciale per la discussione e la condivisione di conoscenze nel campo delle epatiti virali. Il focus sulle terapie e sull'impatto dei trattamenti di Gilead ha suscitato molto interesse, consolidando la collaborazione con la comunità scientifica ed evidenziando l'importanza di una gestione completa dei pazienti affetti da epatite B, C e delta.
Category
🗞
NewsTranscript
00:00 The delta-chronic hepatitis is the most aggressive form of all forms of viral chronic hepatitis.
00:07 It is believed that in Italy there are about 6 to 10 thousand anti-delta-positive subjects.
00:14 In light of this, the Italian Association of Liver Studies Congress at the Centro Congressi Auditorium della Tecnica Roma
00:20 was a crucial moment for the discussion and sharing of knowledge in the field of viral hepatitis.
00:26 The focus on therapies and the impact of Gilead treatments has aroused interest.
00:31 Gilead, consolidating its collaboration with the scientific community,
00:35 has highlighted the importance of a complete management of patients affected by hepatitis B, C and delta.
00:41 The availability of a new drug for the first time in more than 45 years has revolutionized the relationship with the patient
00:49 and is also revolutionizing the quality of life of the patient.
00:55 Most patients do not see the time to start this drug.
00:58 The particularly aggressive delta-chronic hepatitis requires an early diagnosis and a targeted treatment.
01:04 The introduction of the drug Bulevertide has marked a turning point,
01:08 significantly improving the quality of life of patients affected by this disease,
01:13 even if the screening campaign still needs a greater impulse to reach all age groups.
01:19 The screening campaign was born with a delay of almost two years.
01:25 To date, not all regions have deliberated and received this deliberation.
01:31 In hepatitis C, a general screening in four years would pay back the money invested to do the screening.
01:40 Either the idea is moved from health care spending to investment in health care, otherwise we will not get out of it.
01:48 Gilead, with more than 30 years of commitment and innovation in the sector, continues to revolutionize the therapeutic landscape,
01:54 now expanding its range of action also towards new areas, such as the immunological one, thanks to the acquisition of SimaBay.
02:01 Gilead will continue its commitment in the field of hepatitis, also pushing beyond viral hepatitis.
02:12 With the recent acquisition of SimaBay, we will enter the field of the primitive bilial colangitis,
02:18 which is a pathology that has a very high medical need.
02:23 The commitment remains, indeed, it also expands to areas other than the infective one,
02:29 to enter an area of more immunological competence.
02:34 It is important a constant commitment to improve the path of pathology,
02:38 offering innovative therapies to patients, but the goal is also to make the submerged emerge,
02:44 putting the patient at the center of the sphere of action.